

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

SCOTT GILMORE,

Plaintiff,

vs.

MONSANTO COMPANY,

Defendant.

Case No.: 20-cv-01085

JURY TRIAL DEMANDED

FIRST AMENDED COMPLAINT

Plaintiff, SCOTT GILMORE (“Plaintiff”), individually, and on behalf of all others similarly situated, by and through the undersigned counsel, hereby brings this First Amended Class Action Complaint against Defendant, MONSANTO COMPANY (“Defendant” or “Monsanto”) and alleges as follows:

INTRODUCTION

1. This case arises from Monsanto’s wrongful conduct in connection with its manufacture, promotion, marketing, advertising, distribution, labeling, and sale of the Lawn and Garden herbicide Roundup®, which contains the active ingredient glyphosate and other chemicals, including the surfactant polyethoxylated tallow amine (“POEA”).

2. At all relevant times, Monsanto was and is aware Roundup® has the potential to cause users to develop cancer. Monsanto is aware glyphosate is a Class 2A herbicide, meaning

the World Health Organization's ("WHO") International Agency for Research on Cancer ("IARC") has determined it is probably carcinogenic to humans.

3. Monsanto is also aware California has classified glyphosate as a chemical known to cause cancer, such as Non-Hodgkin's lymphoma ("NHL").

4. Monsanto has also known Roundup® and other glyphosate-based herbicides have been banned by many countries, regions, and municipalities throughout the United States and the world because it is dangerous to human health.

5. Monsanto is the defendant in tens of thousands personal injury cases brought by individuals who allege exposure to Roundup® caused their cancer.¹ Three juries found Roundup® likely caused some of those plaintiffs to develop NHL, and awarded nearly \$100 million in compensatory damages and over \$2 billion in punitive damages collectively.²

6. Despite Monsanto's knowledge of Roundup®'s potential carcinogenicity, Monsanto has failed to convey this information to consumers in its promotion, marketing, advertising, distribution, labeling, and sale of Roundup®.

7. Although the Environmental Protection Agency ("EPA") under the current administration has stated glyphosate is not likely to be carcinogenic to humans, Defendant, at the very least, should inform consumers there has been an ongoing scientific dispute over its potential carcinogenicity.

¹ Most of these cases were consolidated in a multi-district litigation ("MDL") before Judge Vince Chhabria in the Northern District of California and have recently settled for a total of approximately \$10 billion.

² As discussed herein, these awards were later reduced by the trial court. One verdict was recently upheld, and the other two are presently on appeal.

8. Monsanto's concealment, suppression, or omission of material facts (*i.e.* the possibility that exposure to Roundup may cause cancer and the ongoing scientific debate about same), with intent that others rely upon such concealment, suppression or omission in connection with its promotion, marketing, advertising, distribution, labeling, and sale of Roundup®, constitutes a violation of Delaware's Consumer Fraud Act ("DCFA"), Del. Code Ann. tit. 6, § 2513.

9. Defendant's violation of the DCFA has caused Plaintiff and members of the Class to suffer an ascertainable loss.

JURISDICTION AND VENUE

10. Jurisdiction is proper in this Court pursuant to the Class Action Fairness Act, 28 U.S.C. § 1332(d) ("CAFA"). Defendant is either incorporated and/or has its principal place of business outside the state in which Plaintiff and members of the proposed Class reside. Furthermore, there are more than 100 Class Members and the amount-in-controversy exceeds \$5,000,000 exclusive of interest and costs.

11. This Court has personal jurisdiction over Defendant because Defendant is a citizen of Delaware and transacts business in the state. Defendant knows that its Roundup products are and were sold throughout Delaware, and caused Roundup to be sold across the United States, including Delaware. In addition, Defendant maintains sufficient contacts with the Delaware such that this Court's exercise of personal jurisdiction over it does not offend traditional notions of fair play and substantial justice.

12. Venue is proper in this District under 28 U.S.C. §1391(b) and (c) because Defendant is a resident of this judicial district and the material omissions giving rise to Plaintiff's claim arose, in part, in Delaware.

PARTIES

13. Plaintiff SCOTT GILMORE is an individual who resides in the State of Washington. Plaintiff seeks injunctive relief and damages on behalf of himself and the Class.

14. Defendant MONSANTO is a Delaware corporation, Delaware Department of State File No. 3174788, with a principal place of business in St. Louis, Missouri. Defendant is engaged in the design, development, manufacture, testing, packaging, promoting, marketing, advertising, distribution, labeling, and/or sale of the Roundup® products at issue in this case.

15. Defendant is a subsidiary of nonparty Bayer AG, a German corporation ("Bayer"). Bayer acquired Monsanto in June 2018 and the merger agreement is governed by Delaware law.

16. The terms "Roundup" and the "Product" refer to all Lawn and Garden formulations of the Roundup® products containing glyphosate sold in the United States, including but not limited to Roundup Ready-To-Use Killer III, Roundup Ready-To-Use Killer III with Sure Shot Wand, Roundup Ready-To-Use Weed & Grass Killer III with Comfort Wand, Roundup Ready-to-Use Weed & Grass Killer III with Pump 'N Go 2 Sprayer, Roundup Precision Gel Weed & Grass Killer, Roundup Ready-To-Use Max Control 365 with Comfort Wand, Roundup Concentrate MAX Control 365, Roundup Ready-To-Use Extended Control Weed & Grass Killer Plus Weed Preventer II with Comfort Wand, Roundup Ready-To-Use Extended Control Weed & Grass Killer Plus Weed Preventer II with Pump 'N Go 2 Sprayer, Roundup Ready-To-Use Extended Control Weed & Grass Killer Plus Weed Preventer II with Trigger Sprayer, Roundup

Concentrate Extended Control Weed & Grass Killer Plus Weed Preventer, Roundup Ready-To-Use Poison Ivy Plus Tough Brush Killer with Trigger Sprayer, Roundup Ready-To-Use Poison Ivy Plus Tough Brush Killer with Comfort Wand, Roundup Concentrate Poison Ivy Plus Tough Brush Killer, Roundup Weed & Grass Killer Concentrate Plus, Roundup Weed & Grass Killer Super Concentrate, or any other formulation thereof containing the active ingredient glyphosate.

17. Defendant has an agreement with its distributor of Roundup, nonparty The Scotts Company, LLC (“Scotts”). Under that agreement, Scotts is responsible for in-store merchandising, store set-up, and other services related to the in-store promotion of Roundup, in a manner consistent with Defendant’s Annual Business Plan. The distribution agreement is governed by Delaware law.

18. Defendant has made and continues to make representations regarding Roundup’s potential health risks through various means of disclosure—for example, representations on its website, in-store advertising, its labeling of Roundup, and through its distribution relationship with Scotts. These means of disclosure originate, in part, in the State of Delaware.

19. During all relevant times, Defendant transacted and conducted business throughout the United States and is responsible for the representations it makes, with respect to Roundup’s potential health risks, throughout the country.

20. Defendant does business in Delaware by consistently selecting its law and forums with respect to Roundup.

FACTUAL ALLEGATIONS

A. Monsanto’s Manufacturing, Promotion, Marketing, Advertising, Distribution, Labeling, and Sale of Roundup.

21. Monsanto was the first company to recognize potential in the chemical glyphosate, a nonselective herbicide that inhibits plant growth through interference with the production of essential aromatic amino acids.

22. Monsanto discovered glyphosate to be an herbicide in 1970 and brought it into the market as Roundup in 1974.

23. All of the Roundup products at issue in this case contain the active ingredient glyphosate, and other components, such as the surfactant POEA,³ which helps glyphosate penetrate plant cells.

24. Roundup is marketed for home and personal use to kill weeds, including weeds in home lawns and gardens. Roundup is sold at retail locations throughout the United States.

25. Monsanto has and continues to promote, market, advertise, and label Roundup as a safe general-purpose herbicide for consumer use. Monsanto has admitted in other legal proceedings that Roundup products are valued by consumers because of their efficacy and safety.

26. Monsanto's promotion, marketing, advertising, and labeling of Roundup leads reasonable consumers into believing Roundup is safe for its intended use.

27. Monsanto, for example, designs the labeling for Roundup. Exemplar photographs of Roundup's front and back labels for the Roundup Ready-to-Use Weed and Grass Killer III are attached hereto as "**Exhibit A.**"

28. Roundup's labeling provides certain warnings, such as, "Keep Out of Reach of Children" and "Caution." But the only hazard identified is that it may cause "moderate eye irritation." *See id.*

³ Monsanto considers POEA to be inert because it does not directly kill plants, it merely enhances glyphosate's ability to do so

29. Roundup's warning gives the false impression eye irritation is the only risk posed by Roundup, when in fact, Roundup has the potential to cause cancer, as discussed more fully herein.

B. The IARC Classification of Glyphosate.

30. The IARC is an intergovernmental cancer agency within the WHO which, in 2015, was tasked with conducting and coordinating research into the causes of cancer as it pertained to glyphosate.

31. In March 2015, an IARC "Working Group" of 17 experts from 11 countries convened to evaluate several insecticides and herbicides, including diazinon, tetrachlorvinphos, malathion, parathion, and glyphosate. The evaluation was based on a cumulative review of all publicly available and pertinent scientific studies. Some of the studies pertained to people exposed to glyphosate through their jobs, such as farmers. Others were experimental studies on cancer and cancer-related effects in experimental systems. The IARC Working Group's full monograph was published on July 29, 2015.

32. In its monograph, the IARC Working Group classified glyphosate as a Class 2A herbicide, which means it is probably carcinogenic to humans. It concluded NHL was most associated with glyphosate exposure.

33. The IARC also found that glyphosate caused DNA and chromosomal damage in human cells.

34. The IARC's conclusions were consistent with scientific developments that had occurred in prior decades.

C. Early Studies and Developments Pertaining to Glyphosate and Roundup's Carcinogenicity and Genotoxicity.

35. As early as the 1980's, Monsanto should have been aware of glyphosate's carcinogenic and genotoxic properties.

36. On March 4, 1985, a group of the EPA's Toxicology Branch published a "consensus review" based on a mouse study conducted by Monsanto in 1983. The review "classified Glyphosate as a Category C oncogen," meaning it is a possible human carcinogen.

37. However in June 1991, EPA published a memorandum entitled, "Second Peer Review of Glyphosate," which changed glyphosate's classification to Group E (evidence of non-carcinogenicity for humans). Two peer review committee members did not concur with the conclusions, and the Memorandum itself "emphasized however, that designation of an agent in Group E is based on the available evidence at the time of evaluation and should not be interpreted as a definitive conclusion that the agent will not be a carcinogen under any circumstances."

38. In 1996, the New York Attorney General sued Monsanto for false and misleading advertising by touting its glyphosate-based Roundup products as, e.g., "safer than table salt" and "practically non-toxic" to mammals, birds, and fish.

39. On November 19, 1996, Monsanto entered into an Assurance of Discontinuance with New York Attorney General, in which Monsanto agreed to alter the advertising, removing from advertisements that represent, directly or by implication, that the weed killers were biodegradable and environmentally friendly. Monsanto also agreed to pay \$50,000 toward New

York's costs of pursuing the case. At the time, New York was the only state to object to the advertising claims.

40. In 1997, Chris Clements, *et al.* published a study entitled, "Genotoxicity of Select Herbicides in *Rana catesbeiana* Tadpoles Using the Alkaline Single-Cell Gel DNA Electrophoresis (Comet) Assay." Genotoxicity refers to the property of chemical agents which cause damage to genetic information within a cell causing mutations, which may lead to cancer. In Clements' publication, tadpoles were exposed to various herbicides, including Roundup, for a 24-hour period. Roundup-treated tadpoles showed "significant DNA damage when compared with unexposed control animals."

41. In 1999, Lennart Hardell and Mikael Eriksson published a study entitled, "A Case–Control Study of Non-Hodgkin Lymphoma and Exposure to Pesticides," which consisted of a population-based case–control study in northern and middle Sweden encompassing 442 cases and twice as many controls was performed. Exposure data were ascertained by comprehensive questionnaires, and the questionnaires were supplemented by telephone interviews. The results indicated exposure to glyphosate and other herbicides yielded increased risks for NHL.

42. In 2002, Julie Marc, *et al.* published a study entitled, "Pesticide Roundup Provokes Cell Division Dysfunction at the Level of CDK1/Cyclin B Activation." The study found Roundup caused delays in the cell cycles of sea urchins. It further noted the deregulations of cell cycle checkpoints are *directly linked* to genomic instability, which can generate diseases and cause cancer. The findings led to the conclusion Roundup "causes changes in cell cycle regulation that may raise questions about the effect of this pesticide on human health."

43. In 2003, A. J. De Roos, et al. published a study entitled, “Integrative assessment of multiple pesticides as risk factors for non-Hodgkin’s lymphoma among men,” which “[r]eported use of several individual pesticides was associated with increased NHL incidence, including . . . glyphosate. A subanalysis of these ‘potentially carcinogenic’ pesticides suggested a positive trend of risk with exposure to increasing numbers.”

44. In 2004, Julie Marc, *et al.* published a study entitled, “Glyphosate-based pesticides affect cell cycle regulation.” In that study, which tested Roundup 3plus on sea urchin eggs, determined “glyphosate-based pesticides are clearly of human health concern by inhalation in the vicinity of spraying,” given the “molecular link between glyphosate and cell cycle dysregulation.” It observed, “roundup may be related to increased frequency of non-Hodgkin’s lymphoma among farmers,” citing the study by A. J. De Roos., *et al.*

45. In 2005, Francisco Peixo published a study entitled, “Comparative effects of the Roundup and glyphosate on mitochondrial oxidative phosphorylation,” which suggested the harmful effects of Roundup could be the result of Roundup’s specific combination of chemicals, and the interaction of glyphosate and the surfactant POEA.

46. In 2008, Mikael Eriksson, *et al.* published a study entitled, “Pesticide exposure as risk factor for NHL including histopathological subgroup analysis,” based on a case-control study of exposure to various pesticides as a risk factor for NHL. Eriksson’s study strengthened previous associations between glyphosate and NHL.

47. In 2009, Nora Benachour and Gilles-Eric Seralini published a study entitled, “Glyphosate formulations induce apoptosis and necrosis in human umbilical, embryonic, and placental cells,” which examined the effects of four different Roundup formulations on human

umbilical, embryonic, and placental cells—at dilution levels far below agricultural recommendations. The study found the formations caused cell death in a few hours in a cumulative manner, caused DNA damage, and found that the formulations inhibit cell respiration. In addition, it was shown the mixture of the components used as Roundup adjuvants, particularly POEA *amplified the action of the glyphosate*. The Roundup adjuvants actually changed human cell permeability and increased the toxicity of glyphosate alone.

48. This study suggests Roundup poses even greater risks than glyphosate alone, as a result of Roundup's specific combination of chemicals, and the interaction of glyphosate and POEA.

D. Glyphosate-Based Herbicides, Including Roundup, are Banned Throughout the World.

49. Following the IARC's report on glyphosate, several countries have issued outright bans or restrictions on glyphosate herbicides, including Roundup.

50. In May 2015, the Netherlands banned all non-commercial use of glyphosate. *See* <https://www.collective-evolution.com/2015/05/30/why-the-netherlands-just-banned-monsantos-glyphosate-based-herbicides/>.

51. In 2016, Italy adopted a law prohibiting the use of glyphosate in areas frequented by the public or by "vulnerable groups" including children and the elderly and in the pre-harvest phase in agriculture. *See* <https://www.soilassociation.org/news/2016/august/italy-bans-toxic-glyphosate/>.

52. In June 2017, the Flemish government approved a ban on glyphosate for individual-use. See <https://www.brusselstimes.com/all-news/belgium-all-news/43150/flemish-government-approves-ban-on-glyphosate-for-individuals/>.

53. In September 2018, the agriculture ministry of the Czech Republic stated the country would ban the blanket use of glyphosate as a weedkiller and as a drying agent. See <https://phys.org/news/2018-09-czech-republic-restrict-glyphosate-weedkiller.html>. The ban came into effect on January 1, 2019. See <http://www.arc2020.eu/czech-out-this-roundabout-way-to-not-ban-roundup/>.

54. In October 2018, the Indian state of Punjab banned the sale of glyphosate. See <https://www.thehindu.com/news/national/other-states/punjab-government-bans-sale-of-herbicide/article25314146.ece>. And in February of 2019, the Indian state of Kerala followed suit, issuing a ban on the sale, distribution and use of glyphosate. See <https://www.thenewsminute.com/article/kerala-government-bans-glyphosate-deadly-weed-killer-96220>.

55. In January 2019, French authorities banned the sale of Roundup following a court ruling that regulators failed to take safety concerns into account when clearing the widely used herbicide. See <https://www.france24.com/en/20190116-weedkiller-roundup-banned-france-after-court-ruling>. In April 2019, a French appeals court ruled Bayer's Monsanto business was liable for the health problems of a farmer who inhaled Roundup. See <https://www.insurancejournal.com/news/international/2019/04/11/523456.htm>.

56. In March 2019, Vietnam announced it has banned the import of all glyphosate-based herbicides. See <https://sustainablepulse.com/2019/03/25/vietnam-bans-import-of-glyphosate-herbicides-after-us-cancer-trial-verdict/#.XS-xCT9Kh9O>.

57. In July 2019, Austria's Parliament passed a bill banning all uses of glyphosate. See <https://www.reuters.com/article/us-austria-glyphosate/austrian-parliament-backs-eus-first-total-ban-of-weedkiller-glyphosate-idUSKCN1TX1JR>. Although the ban was supposed to take effect on January 1, 2020, Austria's Chancellor refused to sign it into law due to a legal technicality. See <https://www.reuters.com/article/us-austria-glyphosate/austrian-leader-blocks-ban-on-weedkiller-glyphosate-citing-technicality-idUSKBN1YD11Z>.

58. In January 2020, Luxembourg issued a total ban on glyphosate. See <https://www.brusselstimes.com/all-news/eu-affairs/92006/luxembourg-will-be-first-eu-country-to-totally-ban-glyphosate/>.

59. Several municipalities and regions in Spain, the United Kingdom, and the United States, have also banned glyphosate herbicides.

E. Monsanto Loses Three Verdicts after Roundup is Found to Cause Cancer in Humans.

60. On August 10, 2018, a unanimous California jury in *Johnson v. Monsanto Co.*, No. CGC16550128 (Cal. Super. Ct., Cnty. of S.F.) found Monsanto's Roundup and Ranger Pro herbicides were unsafe and were a substantial factor in causing harm to the plaintiff. The jury also found Monsanto failed to adequately warn customers of the risks associated with its Roundup and Ranger Pro products, and that the company acted with malice or oppression. The jury awarded the plaintiff a total of \$289 million, with \$250 million in punitive damages and

\$39.25 million in compensatory damages. The court later reduced the punitive damages award, bringing the total award to \$78.5 million. Monsanto appealed the judgment and the California Court of Appeal, on July 20, 2020, affirmed the trial court's judgment, but reduced the total award to \$20.6 million.

61. On March 27, 2019, a unanimous California jury in *Hardeman v. Monsanto Co.*, No. 3:16-cv-00525-VC (N.D. Cal.) found Monsanto liable for failing to warn Roundup could cause cancer, liable for negligence, and liable in a design defect claim. The jury awarded the plaintiff a total of \$80.27 million, with \$75 million in punitive damages and \$5.27 million in compensatory damages. The trial judge later reduced the punitive damages award, bringing the total award to \$25.27 million. Monsanto has appealed the judgment and the matter is currently before the Ninth Circuit Court of Appeals.

62. On May 13, 2019, a California jury found Monsanto likely caused a couple's cancer in *Pilliod v. Monsanto Co.*, No. RG17862702 (Cal. Super. Ct., Cnty. of Alameda). The jury found on a preponderance of the evidence Roundup was a significant contributing factor in causing the plaintiff's NHL. The jury awarded the plaintiffs a total of \$2.055 billion, with \$2 billion in punitive damages and \$55 million in compensatory damages. The court later reduced the punitive and compensatory damages awards, bringing the total award to \$87 million. Monsanto has appealed the judgment and the matter is currently before the California Court of Appeal.

F. Bayer Agrees to Pay Over \$10 Billion to Settle Personal Injury Suits

63. Thousands of other personal injury (including wrongful death) claims have been filed against Monsanto claiming the Product caused the plaintiffs to develop cancer. They have

been coordinated in a multi-district litigation, specifically: *In re Roundup Products Liability Litigation*, Case No. 3:16-md-02741 (N.D. Cal.).

64. On June 24, 2020, Bayer Corporation, the maker of Roundup and owner of Monsanto, announced it had reached a \$10.1 billion settlement to resolve tens of thousands of personal injury cases coordinated in a multi-district litigation (“MDL”) in the Northern District of California. These cases were brought by individuals who claim their use of Roundup caused their non-Hodgkin’s Lymphoma (i.e., “NHL”). *See In re Roundup Products Liability Litigation*, Case No. 3:16-md-02741..

65. In addition to, but separate from, the individual personal injury cases, Bayer resolved a proposed “future claims” class action on behalf of everyone who was exposed to Roundup (but had not yet hired a lawyer to bring a tort claim, with subclasses for people who already have cancer and those who do not) for an *additional* \$1.1 billion. This causation-focused “future claims” class action complaint was filed on June 24, 2020, concurrent with a motion for preliminary approval. The “future claims” class action complaint seeks certification of an issue class under Rules 23(b) and (c)(4) for “a litigated determination of the general causation dispute on a class-wide basis”. *See id.* at *In re Roundup Products Liability Litigation*, Case No. 3:16-md-02741, Dkt. No. 11042 (N.D. Cal. June 24, 2020) (Motion for Preliminary Approval of Class Action Settlement).

66. The “future claims” class settlement was withdrawn after the judge in the MDL expressed concerns about the terms. Had the proposed “future claims” class settlement ultimately been approved by the Court, it would have bound all individuals who were exposed to Roundup at any time in any manner, but who had not yet retained counsel. *Id.*

67. Several of the “future claims” class action complaint and settlement terms—most notably the proposed class notice—support Plaintiff’s claims in the instant lawsuit. For example, in the \$50 million Monsanto-funded notice plan for the “future claims” class settlement, Monsanto agreed to notify class members of Roundup’s potential to cause cancer by direct mail, email, posters for retailers to display in their stores, and through multi-national and local media. *Id.* As later discussed herein, this is essentially *the same form of relief Plaintiff seeks here*: disclosure of Roundup’s potential carcinogenicity in a manner not involving a label change.

68. If approved, the proposed notice plan would have alerted “future claims” class members to the creation of a registration process to encourage class members to come forward and identify themselves and establish eligibility for certain “class benefits.” *Id.* The class benefits in the “future claims” class settlement included a Diagnostic Accessibility Grant Program (“DAGP”), which is a medical outreach and assistance program that would have distributed grants to existing medical clinics and healthcare providers offering diagnostic services to class members who have not been diagnosed with NHL (representing 18% of the settlement fund). *Id.* The “future claims” settlement also included Interim Assistance Grants (“IAGs”) to compensate class members diagnosed with NHL for the effects of the delay during the litigation standstill on an as-needed basis (representing 77% of the settlement fund). *Id.* Furthermore, the class benefits included a Research Funding Program (“RFP”), which would have funded medical and scientific research into the diagnosis and treatment of NHL (representing 5% of the settlement fund). *Id.* Notice would have been targeted to “large groups of individuals who may be itinerant, lack exposure to traditional media, or do not speak English as a first language.” *Id.*

69. The approximately 200-page “future claims” class settlement agreement also included the creation of an independent “Class Science Panel,” which would have considered a closed set of materials and issue “a binding and determinative” answer to the question of whether exposure to Roundup can cause non-Hodgkin’s lymphoma in humans. *Id.* The Class Science Panel would have been required, under the terms of the proposed class settlement, to issue its causation finding in four years, but not may do so earlier. *Id.* In exchange, “future claims” class members—broadly defined as anyone ever exposed to Roundup (who, as of June 24, 2020, had not retained counsel)—would have forever waived their right to punitive damages and be barred from filing a case against Monsanto during this four-year period. *Id.* In the meantime, the \$1.1 billion would have been used to provide immediate relief to diagnose or ameliorate NHL and compensate for delay (by providing the aforementioned “class benefits”). *Id.*

70. The Class Science Panel’s decision would have been binding on future litigants, and, in exchange, class members would have forever waived their right to punitive damages. By agreeing to the creation of this panel and by *agreeing to be bound* by the result in all future personal injury litigation, Monsanto acknowledged the existence of an ongoing scientific dispute as to whether exposure to Roundup has the potential to cause NHL.⁴

G. California’s Classification of Glyphosate as a Chemical Known to Cause Cancer.

71. On July 7, 2017, following the IARC’s classification of glyphosate, California’s Office of Environmental Health Hazard Assessment (OEHHA) listed glyphosate as a chemical

⁴ Putative Class Counsel’s swift withdrawal of the motion for preliminary approval of the class settlement following Judge Chhabria’s comments questioning the viability of the settlement does not change the fact that Bayer filed a document in Federal Court acknowledging there is a possibility that exposure to Roundup may in fact cause cancer (and agreed to pay \$1.1 billion in an effort to resolve this dispute).

known to the State of California to cause cancer, pursuant to the Safe Drinking Water and Toxic Enforcement Act of 1986 (“Proposition 65”).

72. Proposition 65 prohibits retailers and manufacturers from knowingly and intentionally exposing California consumers to a chemical known to the State of California to cause cancer or developmental or reproductive harm without first providing a “clear and reasonable warning.”

73. In response to OEHHA’s inclusion of glyphosate on the Proposition 65 list, Monsanto, CropLife America, and several growers associations filed a motion alleging the IARC classification of glyphosate is contrary to the international scientific consensus and that requiring a Proposition 65 warning would be misleading to the ordinary consumer.

74. On February 26, 2018, the Eastern District Court of California issued a preliminary injunction precluding OEHHA from enforcing its Proposition 65 warning requirements against glyphosate registrants, which would have taken effect on July 7, 2018. This injunction was made permanent on June 22, 2020. The Court however did not rule that glyphosate should be removed from the Proposition 65 list.

75. On August 7, 2019, EPA’s Office of Pesticide Program (“OPP”) issued a letter to registrants of glyphosate products (the “OPP Letter”) stating a Proposition 65 warning statement on glyphosate-based products would be “false and misleading” and would render them misbranded under FIFRA. The OPP letter was not the product of any formal proceedings, nor was it published in the Federal Register.

H. The EPA’s Registration Review for Glyphosate

76. Since glyphosate's first registration, EPA has reviewed and reassessed its safety and uses, including undergoing registration review, a program that re-evaluates each registered pesticide on a 15-year cycle.

77. In January 2020, after receiving and considering public comments, EPA issued its Interim Registration Review Decision for glyphosate, finding "there are no risks to human health from the current registered uses of glyphosate and that glyphosate is not likely to be carcinogenic to humans." EPA stated it "will continue to monitor the open literature for studies that use scientifically sound and appropriate methodology and relevant routes of exposure that have the potential to impact the risk evaluation of glyphosate."⁵

78. EPA's review of glyphosate, however, was based on an incomplete and distorted factual record, largely due to efforts on the part of Monsanto to conceal glyphosate's risks. As described herein, Monsanto withheld relevant scientific evidence from EPA, in violation of federal law, and manipulated the scientific debate about glyphosate-based herbicides by "ghostwriting" scientific papers.

79. Through the numerous personal injury and wrongful death lawsuits filed against Monsanto, which total in the tens of thousands, Monsanto obtained extensive medical documentation showing a link between Roundup and various types of cancer.

80. The plaintiffs in the three California cases resulting in favorable jury verdicts for the plaintiffs (as described above) submitted medical records and expert testimony showing that

⁵ As of March 2020, multiple groups have sued EPA over its Interim Registration Review Decision for glyphosate. These groups include Center for Food Safety, Beyond Pesticides, the Rural Coalition, Organización en California de Lideres Campesinas, the Farmworker Association of Florida, Natural Resources Defense Council, and Pesticide Action Network North America.

Roundup caused those plaintiffs to develop cancer. Importantly, all of this medical documentation and information would have been provided to the Monsanto.

81. Despite the exorbitant amount of medical information in Monsanto's possession that Roundup and/or glyphosate can cause cancer, as generated just by the three California cases, Monsanto did not turn any of this information over to EPA.

82. Monsanto failed to comply 40 C.F.R. § 159.152, which requires "applicants to submit, as part of an application for registration, any factual information of which [it] is aware regarding unreasonable adverse effects of the pesticide on humans or the environment." *Id.* Defendant's refusal to provide such information, including medical records and information provided to Monsanto in the thousands of personal injury lawsuits, to EPA constituted deception by omission and deprived this agency from making an informed decision as to whether Roundup is safe for human exposure and further deprived the opportunity for EPA from reaching an informed conclusion regarding Roundup's potential carcinogenicity.

83. Defendant indeed has had a history of misleading the EPA regarding Roundup's potential carcinogenicity, by deception and omission.

84. Beginning in the 1990s, as numerous studies found an association between Roundup and Non-Hodgkin Lymphoma (as described herein *supra*), Monsanto hired Dr. James Parry, a world-renowned genotoxicologist, to rebut the growing scientific consensus Roundup is genotoxic. This tactic backfired: Following his review, Dr. Parry provided a report to Monsanto that "glyphosate is capable of producing genotoxicity both in vivo and in vitro" Dr. Parry recommended that Monsanto conduct research on the genotoxicity of glyphosate-based

herbicides; the mechanisms giving rise to genotoxicity; and the relevance of these mechanisms to the safety of glyphosate-based herbicides.

85. Monsanto decided not to conduct the research Dr. Parry asked it to perform. Dr. Parry offered to conduct the research himself, but Monsanto refused. Monsanto's goal was not actually to determine whether glyphosate-based herbicides caused cancer but rather to find an expert that could influence regulators when genotoxicity issues arise. Monsanto failed to produce the Parry Report to EPA as required under 40 C.F.R. § 159.158. Because Dr. Parry never came around to Monsanto's view of the science, Monsanto would not let him speak to regulators and his report was never submitted to EPA.

86. Monsanto has also engaged in the practice of "ghostwriting" scientific papers to establish the safety of glyphosate-based herbicides, which, when published, appear to be authored by independent academic scientists.

87. A noteworthy example is a paper published in 2000 purportedly written by G. M. Williams, *et al.* entitled, "Safety evaluation and risk assessment of the herbicide roundup and its active ingredient, glyphosate, for humans." This paper concluded "Roundup herbicide does not pose a health risk to humans." Although no Monsanto employee is listed as an author, William Heydens, a Monsanto employee, admits that he wrote the manuscript and provided final edits to the paper. EPA has consistently relied on this paper when considering the safety of glyphosate-based herbicides.

88. Another example of Monsanto's surreptitious involvement in the science of glyphosate can be found in a memo dated August 4, 2015 by Monsanto scientist David Saltmiras, stating he "ghost wrote cancer review paper Greim, et al. (2015)." That paper, entitled,

“Evaluation of carcinogenic potential of the herbicide glyphosate, drawing on tumor incidence data from fourteen chronic/carcinogenicity rodent studies,” concluded “glyphosate does not present concern with respect to carcinogenic potential in humans.” EPA has consistently relied on this paper when considering the safety of glyphosate-based herbicides.

89. Immediately after IARC deemed glyphosate a probable carcinogen, Monsanto devised a response plan that included convening an expert panel to “[p]ublish comprehensive evaluation of carcinogenic potential by credible scientists” that could later be used for litigation support. It worked with Intertek, an industry consultancy firm, to create a false impression that the expert panel was independent.

90. On September 28, 2016, the “independent” expert panel published its conclusions in the journal *Critical Reviews in Toxicology*, in a paper entitled “A review of the carcinogenic potential of glyphosate by four independent expert panels and comparison to the IARC assessment.” The paper concluded glyphosate was “unlikely to pose a carcinogenic risk to humans.”

91. Included in the paper was a “Declaration of Interest,” which stated: “[t]he Expert Panelists . . . were not directly contacted by the Monsanto Company” and that “neither any Monsanto company employees nor any attorneys reviewed any of the Expert Panel’s manuscripts prior to submission to the journal.” These statements were blatantly false. Monsanto recruited, selected, and had direct contact with the experts, some of them receiving payments from Monsanto. Moreover, Monsanto was engaged in organizing, reviewing, and editing of the drafts, and had ultimate authority over the paper’s content.

92. The foregoing represent just a handful of the many scientific articles ghostwritten by Monsanto to manipulate the scientific debate about glyphosate-based herbicides, including Roundup, and to prevent regulators like EPA from learning their true risks.

I. Monsanto's Failure to Warn Consumers of Roundup's Carcinogenic Properties.

93. Defendant's promotion, marketing, advertising, distribution, and labeling of Roundup leads reasonable consumers into believing Roundup is safe for its intended use, when it is not. Exposure to Roundup has the potential to cause cancer in humans, as explained herein.

94. Defendant does not warn consumers of Roundup's potential to cause cancer or, at least, that there is a vigorous scientific dispute about Roundup's potential to cause NHL in humans.

95. Customers rely on Defendants to offer quality and safe products. But instead of putting its customers' safety first and informing consumers about Roundup's potential health risks, Defendant manufactured, labeled, and marketed a potentially deadly product without any warning, all for its own financial benefit.

96. Defendant's focus on its own financial gain is evidenced by its refusal to submit medical information evidencing a link between Roundup and cancer to EPA.

97. Defendant was aware of the substantial danger to consumers while using Roundup, however Defendant did not notify consumers that exposure to Roundup could potentially cause cancer, including NHL.

98. Defendant could and can notify consumers of the potential health risks by, among other things, providing information on its webpages for Roundup, in television and radio commercials, in-store signage, such as point-of-sale or shelf tags, posters, or press releases—yet

has not done so.

99. Plaintiff and other consumers were not warned by Monsanto and therefore did not know that using Roundup exposed them to chemicals that are hazardous and potentially carcinogenic to humans.

100. Whether exposure to Roundup has the potential to cause cancer in humans would be important in a consumer's decision whether to purchase Roundup.

101. The existence of an ongoing scientific debate about whether exposure to Roundup Products can cause NHL in humans would also be important in a consumer's decision whether to purchase Roundup.

J. Plaintiff's Purchase of Roundup

102. During the Class Period,⁶ Plaintiff has resided in Oregon and the State of Washington.

103. Plaintiff has purchased Roundup Ready-to-Use Weed & Grass Killer III on multiple occasions, and his most recent purchase was in December 2018 from a Home Depot⁷ located in Multnomah County, Oregon.

104. When Plaintiff purchased the Roundup Ready-to-Use Weed & Grass Killer III, neither the Roundup label, nor in-store advertisements, nor Monsanto's webpages disclosed Roundup had the potential to cause cancer or, at the very least, that there was an ongoing scientific dispute concerning its potential carcinogenicity.

105. Had Plaintiff known exposure to Roundup had the potential to cause cancer, or that there was an ongoing scientific dispute concerning its potential carcinogenicity, he would not

⁶ The "Class Period" is defined as August 19, 2017 through the date a class is certified.

⁷ Home Depot U.S.A., Inc. is a Delaware corporation.

have purchased it.

106. Plaintiff learned Roundup had the potential to cause cancer after purchasing the Roundup Ready-to-Use Weed & Grass Killer III. At that time, Plaintiff stopped using the Product, which had not yet been consumed in its entirety.

107. Plaintiff, however, found Roundup to be effective, and is thus at risk of purchasing one of the 17 different Roundup products because Defendant does nothing to disclose Roundup's potential health risks. Plaintiff (and the Class) have no way of knowing if Roundup remains dangerous to human health, so long as the dozens of varieties of Roundup continue to be for sale without any disclosures, in any manner from any source in the stream of commerce, that it is potentially dangerous. This information would not only be important to Plaintiff (and the Class') decision to buy Roundup again in the future, but would also enable him (and the Class) to make informed decisions about the frequency and manner in which he purchases (and uses) the product.

108. Absent injunctive relief requiring Defendant to stop selling Roundup or to provide its customers with additional information, Plaintiff will be unable to rely on Defendant's representations (or lack thereof) about Roundup's safety in the future. Indeed, as long as Roundup is available for purchase without any type of warning, Plaintiff is at risk future economic injury.

K. Plaintiff's Measurable Economic Injury

109. Plaintiff and the Class paid a price premium for the Product given Roundup's potential carcinogenicity was undisclosed. Indeed, Defendant has implicitly advertised Roundup

as safe, and thus “superior” to other weed and grass killers on the market. As such, the product is worth less than Plaintiff and the Class paid.

110. Had Defendant disclosed Roundup’s links to cancer, it would not have been able to command such a high price. In other words, but for Defendant’s omissions, the actual price Plaintiff and Class Members paid would have and should have been less.

CLASS ALLEGATIONS

111. Plaintiff re-alleges and incorporates by reference the allegations set forth in each of the preceding paragraphs of this Class Action Complaint as if fully set forth herein.

112. Plaintiff brings this class action pursuant to Rule 23(b)(2) and 23(b)(3) of the Federal Rules of Civil Procedure on behalf of himself and all members of the following Class (the “Class”):

All persons who purchased at least one Product in the United States since August 19, 2017.

113. The following are excluded from the Class: Defendant, its parent company, subsidiaries, affiliates, and employees; all persons who make a timely election to be excluded from the Class; governmental entities; and the Judge(s) to whom this case is assigned and any immediate family members thereof.

114. Certification of Plaintiff’s claims for class-wide treatment is appropriate because Plaintiff can prove the elements of Plaintiff’s’ claims on a class-wide basis using the same evidence as would be used to prove those claims in individual actions alleging the same claims.

A. Federal Rules of Civil Procedure, Rule 23(a) Factors.

115. **Numerosity:** The members of the Class are so numerous that individual joinder of all class members is impracticable. The precise number of members of the Class is unknown to

Plaintiff, but it is clear that the number greatly exceeds the number that would make joinder practicable, particularly given Defendants' comprehensive distribution and sales network throughout the United States.

116. Members of the Class may be notified of the pendency of this action by recognized, Court-approved notice dissemination methods, which may include U.S. Mail, electronic mail, Internet postings, in-store signage, shelf tags, and/or published notice in newspapers, magazines, or other periodicals.

117. **Commonality.** This action involves common questions of law or fact, which predominate over any questions affecting individual members of the Class. All members of the Class were exposed to Defendants' deceptive and misleading advertising and marketing claims and/or omissions alleged herein. Common questions of law or fact include:

- a. whether Defendant, in its promotion, marketing, advertising, and labeling of Roundup, concealed, suppressed, or omitted material facts—i.e. Roundup's potential to cause cancer;
- b. whether Defendant acted with the intention that others rely on such concealment, suppression or omission;
- c. whether Defendant's concealment, suppression or omission of Roundup's potential to cause cancer is material to reasonable consumers;
- d. whether Defendant's promotion, marketing, advertising, and labeling of Roundup caused Plaintiff and the Class to suffer an ascertainable loss;
- e. whether Defendant violated the DCFA;

- f. whether Plaintiff and the other members of the Class are entitled to damages under the DCFA; and
- g. whether Plaintiff and the other members of the Class are entitled to injunctive relief and/or declaratory relief under the DCFA.

118. Defendant engaged in a common course of conduct in contravention of the laws Plaintiff seeks to enforce individually, and on behalf of the other members of the Class. Similar or identical statutory legal violations, business practices, and injuries are involved. Individual questions, if any, pale by comparison, in both quality and quantity, to the numerous common questions that dominate this action. Moreover, the common questions will yield common answers.

119. **Typicality.** Plaintiff's claims are typical of the claims of the other members of the Class because, among other things, all members of the Class were comparably injured through the same uniform misconduct described herein. Further, there are no defenses available to Defendant that are unique to Plaintiff.

120. **Adequacy.** Plaintiff, SCOTT GILMORE, is an adequate representative of the members of the Class because his interests do not conflict with the interests of the other members of the Class that Plaintiff seeks to represent. Plaintiff has retained counsel competent and experienced in complex class action litigation and Plaintiff will prosecute this action vigorously. The Class' interests will be fairly and adequately protected by Plaintiff and Plaintiff's counsel. Undersigned counsel has represented consumers in a wide variety of actions where they have sought to protect consumers from fraudulent and deceptive practices.

B. Federal Rules of Civil Procedure, Rule 23(b)(2) Factors.

121. Defendant has acted or refused to act on grounds generally applicable to Plaintiff and members of the Class, thereby making appropriate final injunctive relief and declaratory relief, as described herein, with respect to the members of the Class as a whole.

122. Injunctive relief is necessary to prevent further fraudulent and unfair business practices by Defendant. Money alone will not afford adequate and complete relief, and injunctive relief is necessary to restrain Defendant from continuing to sell Roundup without informing its customers that using Roundup may be carcinogenic.

C. Federal Rules of Civil Procedure, Rule 23(b)(3) Factors.

123. **Common Issues Predominate:** As set forth in detail hereinabove, common issues of fact and law predominate because Plaintiff's claims are based on a deceptive common course of conduct. Whether Defendant's conduct is likely to harm reasonable consumers and violate the UCL is common to all members of the Class and are the predominating issues, and Plaintiff can prove the elements of her claims on a class-wide basis using the same evidence as would be used to prove those elements in individual actions alleging the same claims.

124. **Superiority.** A class action is superior to other available methods for the fair and efficient adjudication of this controversy for at least the following reasons:

- a. Given the size of the claims of individual Class members, as well as the resources of Defendant, few Class members, if any, could afford to seek legal redress individually for the wrongs alleged herein;
- b. This action will permit an orderly and expeditious administration of the claims of Class members, will foster economies of time, effort, and expense and will ensure uniformity of decisions;

- c. Any interest of Class members in individually controlling the prosecution of separate actions is not practical, creates the potential for inconsistent or contradictory judgments and would create a burden on the court system; and
- d. Without a class action, Class members will continue to suffer damages, Defendant's violations of law will proceed without remedy, and Defendant will continue to reap and retain the substantial proceeds derived from its wrongful and unlawful conduct. Plaintiff and Class members have suffered damages as a result of Defendant's unlawful and unfair conduct. This action presents no difficulties that will impede its management by the Court as a class action.

CAUSE OF ACTION

COUNT I: VIOLATION OF THE DELAWARE CONSUMER FRAUD ACT ("DCFA"),

Del. Code Ann. tit. 6, § 2511, et seq.

125. Plaintiff realleges and incorporates by reference the allegations set forth in the preceding paragraphs as if fully set forth herein.

126. The Delaware Consumer Fraud Act ("DCFA") prohibits any "act, use or employment by any person of any deception, fraud, false pretense, false promise, misrepresentation, or the concealment, suppression, or omission of any material fact with intent that others rely upon such concealment, suppression or omission, in connection with the sale, lease or advertisement of any merchandise, whether or not any person has in fact been misled, deceived or damaged thereby" Del. Code Ann. tit. 6, § 2513.

127. The purpose of the DCFA is "to protect consumers and legitimate business enterprises from unfair or deceptive merchandising practices in the conduct of any trade or

commerce in part or wholly within this State.” Del. Code Ann. tit. 6, § 2512.

128. Defendant was, at all times relevant hereto, a “person” as defined by Del. Code Ann. tit. 6, § 2511(7).

129. Roundup was, at all times relevant hereto, “merchandise” as defined by Del. Code Ann. tit. 6, § 2511(6).

130. Defendant engaged in the “sale” and “advertisement” of Roundup as defined by Del. Code Ann. tit. 6, §§ 2511(1), (8), 2513.

131. Defendant indeed was responsible for the manufacture, promotion, marketing, advertising, distribution, labeling, and sale of Roundup.

132. Defendant concealed, suppressed, or omitted material facts with intent that others rely upon such concealment, suppression or omission, in violation of Del. Code Ann. tit. 6, § 2513.

133. Specifically, Defendant failed to disclose—on the Roundup label, on its webpages, on in-store advertisements, and through other means of disclosure—Roundup’s potential to cause cancer including, at the very least, the existence of an ongoing scientific debate as to whether exposure to Roundup can cause NHL in humans.

134. Defendant should have been aware of the risks of Roundup due to the information available to it, particularly since Defendant manufactures the Products, *supra*.

135. The facts Defendant concealed, suppressed, or omitted are material because a reasonable consumer would consider them important factors in deciding whether to purchase Roundup.

136. Defendant’s omissions were uniform and material and constituted a continuing

course of conduct of misleading and deceptive business practices.

137. Plaintiff did not know exposure to Roundup has the potential to cause cancer at the time he purchased it. Plaintiff would not have purchased Roundup had he known it had the potential to cause cancer, or that there has been an ongoing scientific debate as to whether exposure to Roundup can cause NHL in humans.

138. Plaintiff suffered an economic injury because the economic benefit he received in purchasing Roundup was worth less than the economic benefit for which he bargained due to its potential carcinogenicity.

139. Plaintiff may purchase Roundup again if he believes it has been reformulated to remove or mitigate its potential risks.

140. Plaintiff is entitled to bring this Action under the DCFA for damages. *See Del. Code Ann.* tit. 6, § 2525 (“A private cause of action shall be available to any victim of a violation of this subchapter”).

141. Plaintiff is also entitled to injunctive relief under the DFCA. *See Del. Code Ann.* tit. 6, § 2523. For example, Plaintiff alleges an order requiring Defendant to notify consumers of Roundup’s potential to cause cancer (or, at least, the existence of a scientific dispute about whether exposure to Roundup causes NHL) may be appropriate. Defendant could disclose this information on its webpages for the Roundup products, by asking retailers to post notice near where Roundup is sold, and/or presenting this information through various media, for example, on local television and radio, in consumers magazines, and on social media—all of which may be accomplished without changing the Roundup label.

142. Plaintiff is entitled to reasonable costs and attorneys’ fees in pursuit of this Action.

143. Plaintiff seeks all available remedies, damages, and awards as a result of Defendants violations of DCFA.

PRAYER FOR RELIEF

WHEREFORE, Plaintiff, individually, and on behalf of all other similarly situated, prays for relief pursuant to each cause of action set forth in this Complaint as follows:

- i. For an award of equitable relief for the cause of action set forth in Count I as follows:
 - a. Enjoining Defendant from continuing to engage, use, or employ any unlawful business acts or practices related to the manufacture, promotion, marketing, advertising, distribution, and sale of Roundup in violation of the DCFA;
 - b. Enjoining Defendant from continuing to sell Roundup unless and until it complies with 40 C.F.R. § 159.152;
- ii. For actual damages in an amount to be determined at trial for the cause of action set forth in Count I;
- iii. For an award of attorney's fees and costs;
- iv. For any other relief the Court might deem just, appropriate, or proper; and
- v. For an award of pre- and post-judgment interest on any amounts awarded.

Respectfully submitted,

DATE: January 12, 2021

RHODUNDA WILLIAMS & KONDRASCHOW

By: /s/ William J. Rhodunda, Jr.

Chandra J. Williams (No. 4907)
Brandywine Plaza West
1521 Concord Pike, Suite 205
Wilmington, DE 19803
(302) 576-2000 (telephone)
(302) 576-2004 (facsimile)
Bill@rawlaw.com
Chandra@rawlaw.com

-and-

MILSTEIN JACKSON
FAIRCHILD & WADE, LLP
Gillian L. Wade (to be admitted *pro hac vice*)
gwade@mjfwlaw.com
Sara D. Avila (to be admitted *pro hac vice*)
savila@mjfwlaw.com
Marc A. Castaneda (to be admitted *pro hac vice*)
mcastaneda@mjfwlaw.com
10250 Constellation Boulevard
14th Floor
Los Angeles, California 90067
Telephone: (310)396-9600
Facsimile: (310)396-9635
Email: gwade@mjfwlaw.com



